Trial · NCT07898306
Nasal Residency of HEX17
NCT07898306, Phase 1, Not yet recruiting, Pneumagen Ltd, a subsidiary of NorthLinks Bio
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Nasal Residency of HEX17. Trials, record NCT07898306. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07898306
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Nasal Residency of HEX17
- NCT number
- NCT07898306
- Status
- Not yet recruiting
- Phases
- Phase 1
- Enrollment
- 44 participants, estimated
- Lead sponsor
- Pneumagen Ltd, a subsidiary of NorthLinks Bio
- Conditions
- Healthy Volunteers
- Interventions
- HEX17, Placebo
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Detection of HEX17 Bound to Nasal Epithelial Cells (Part A) | Up to Day 1 | Detection of HEX17 bound to nasal epithelial cells collected by nasal brushing and analysed using FACS. |
| Primary | Presence of HEX17 in Nasal Epithelial Cells Following Different Dosing Regimens (Part B) | Up to Day 43 | Assessment of the presence and persistence of HEX17 in nasal epithelial cells following intranasal administration using different dosing regimens. |
| Secondary | The number and Severity of Adverse Events | Part A: From first dose on Day 1 until completion of follow-up assessments on Day 8 (up to 8 days). Part B: From first dose until completion of follow-up assessments after the final dose of IMP (up to 43 days). | Assessment of the number, severity and relationship of adverse events following administration of HEX17 or placebo. |
| Secondary | Change in Nasal Examination Findings | Up to Day 43 | Assessment of changes from baseline in nasal mucosal examination findings. |
| Other | Systemic Presence of HEX17 in Blood Measured by a Validated HEX17 Concentration Assay (Part B). | Up to Day 29 | Presence or absence of HEX17 in blood collected at pre-dose and post-dose on the first and last dosing days. |
| Other | Detection and Quantification of HEX17 Associated With Nasal Epithelial Cells Using an Alternative Analytical Method | From first dose until nasal epithelial sampling (up to Day 43). | Presence or absence of HEX17 and, where feasible, amount of HEX17 associated with nasal epithelial cells collected by nasal brushing, measured by an analytical method other than FACS. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07898306
GET https://conductscience.org/api/trials/v1/NCT07898306/registered